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A 30-year-old, primigravid woman was referred to the
hospital at 24 weeks’ gestation because of fetal car-
diac abnormalities detected by sonography. The woman
and her husband were nonconsanguineous and healthy,
and there was no family history of congenital heart
defects or DiGeorge syndrome (DGS). She did not
have diabetes mellitus and denied any exposure to ter-
atogenic agents or infectious diseases during this preg-
nancy. Level II ultrasound revealed a singleton fetus
with a fetal biometry equivalent to 24 weeks’ gesta-
tion, a normal thymus, a normal amount of amniotic
fluid, double-outlet right ventricle, pulmonary steno-
sis, and a ventricular septal defect. Amniocentesis was
performed. Bacterial artificial chromosome array com-
parative genomic hybridization (aCGH) and oligonu-
cleotide aCGH were applied for genetic analysis using
cultured amniocytes. Bacterial artificial chromosome
aCGH demonstrated a 22q11.21 microdeletion (RP11-
690P21RP11-1116M14; (Figure 1). Oligonucleotide
aCGH demonstrated a 2.6-Mb deletion in 22q11.21
(chromosome 22, 17141308-19792353 bp; Figure 2).
G-banded chromosome analysis at the 850-band 
level revealed a 46,XX karyotype. Fluorescence in situ
hybridization (FISH) using dual color DNA probes
showed a heterozygous deletion of the DGS/velocar-
diofacial syndrome (DGS/VCFS) region (Figure 3).
FISH chromosome analysis revealed a 46,XX.ish del
22Q11.2 MICRODELETION IN A FETUS WITH
DOUBLE-OUTLET RIGHT VENTRICLE, PULMONARY
STENOSIS AND A VENTRICULAR SEPTAL DEFECT:
PRENATAL DIAGNOSIS BY ARRAY COMPARATIVE
GENOMIC HYBRIDIZATION
Chih-Ping Chen1,2,3,4,5,6*, Yi-Ning Su7, Tung-Yao Chang8, Schu-Rern Chern2, 
Fuu-Jen Tsai4,9,10, Jonathan Kwei Hwang11, Wayseen Wang2,12
Departments of 1Obstetrics and Gynecology and 2Medical Research, Mackay Memorial Hospital, Taipei, 3Department of
Biotechnology, Asia University, 4School of Chinese Medicine, College of Chinese Medicine, China Medical University, 
Taichung, 5Institute of Clinical and Community Health Nursing and 6Department of Obstetrics and Gynecology, School of
Medicine, National Yang-Ming University, 7Department of Medical Genetics, National Taiwan University Hospital, 8Taiji Fetal
Medicine Center, Taipei, Departments of 9Medical Genetics, and 10Medical Research, China Medical University Hospital, 
Taichung, Taiwan, 11Loyola Marymount University, Los Angeles, USA, and 12Department of 
Bioengineering, Tatung University, Taipei, Taiwan.
*Correspondence to: Dr Chih-Ping Chen, Department
of Obstetrics and Gynecology, Mackay Memorial
Hospital, 92, Section 2, Chung-Shan North Road,
Taipei, Taiwan.
E-mail: cpc_mmh@yahoo.com
Accepted: July 17, 2009
Figure 1. Bacterial artificial chromosome array comparative
genomic hybridization using CMDX bacterial artificial chro-
mosome array comparative genomic hybridization CA2500
chips (CMDX, Irvine, CA, USA) showing a 22q11.21 micro-
deletion [arr cgh 22q11.21q11.21 (RP11-690P21RP11-
1116M14) × 1].
0
50
45
40
35
30
25
20
15
10
5
.22.33.567 1.521 4.53
p13
p12
p11.2
p11.1
q11.1
q11.21
q11.22
q11.23
q12.1
q12.2
q12.3
q13.1
q13.2
q13.31
q13.32
q13.33
Ratio
Chromosome 22
(22)(q11.2q11.2)(D22S553–) karyotype. Microarray-
based chromosome analysis showed arr 22q11.21
(17141308-19792353) × 1.
The 22q11.2 deletion has an estimated incidence
of 1 per 4,000 live births [1] and has been detected in
the majority of patients with DGS, VCFS and conotrun-
cal anomaly face syndrome, as well as in some patients
with Opitz G/BBB syndrome and Cayler cardiofacial
syndrome [2–5], all of which are referred to as the
22q11.2 deletion syndrome [5]. The 22q11.2 deletion
syndrome is characterized by congenital heart defects,
aplasia or hypoplasia of the thymus with immune de-
ficiency, small or absent parathyroid glands with hypo-
calcemia, palatal abnormalities with speech disorders,
and cognitive difficulties [5]. Indications for prenatal
testing for the 22q11.2 deletion syndrome include 
a previous child with DGS/VCFS or a 22q11.2 dele-
tion, an affected parent with DGS/VCFS or a 22q11.2
deletion, and a sonographic finding of conotruncal
cardiac defects [5]. Reported prenatal sonographic
features associated with a 22q11.2 microdeletion
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Figure 2. Oligonucleotide array comparative genomic hybridization using HumanCytoSNP-12 v1 BeadChips (Illumina, San
Diego, CA, USA) showing a 2.6-Mb deletion in 22q11.21 [arr 22q11.21 (17141308-19792353) × 1].
Figure 3. Fluorescence in situ hybridization using Vysis LSI
DiGeorge/velocardiofacial syndrome region/ARSA dual color
DNA probes with a 22q13.3 telomere probe (LSI ARSA; green
signal) and a DiGeorge critical region probe at 22q11.2 (LSI
DiGeorge/velocardiofacial syndrome; red signal) (all probes
by Abbott Laboratories, Abbott Park, IL, USA) showing a
normal chromosome 22 (one red signal and one green signal)
and a del(22)(q11.2q11.2) chromosome (green signal only)
in a metaphase amniocyte.
include conotruncal cardiac malformations, increased
nuchal translucency (NT), polyhydramnios, intrauterine
growth restriction, extracardiac anomalies, severe pul-
monary artery anomalies, and thymic hypoplasia [6–12].
The present case did not present with increased NT, poly-
hydramnios, thymic hypoplasia or intrauterine growth
restriction, but did show cardiac and pulmonary artery
anomalies on prenatal ultrasound.
Lautrup et al [13] found that none of 146 fetuses
with NT above the 99th centile (> 3.5 mm) and a nor-
mal karyotype was diagnosed with a 22q11 microde-
letion by either multiplex ligation-dependent probe
amplification or FISH, and they estimated that the
prevalence of a 22q11 microdeletion in these other-
wise normal fetuses with increased NT was below 2.7%.
In a study of 540 fetuses with prenatally detected car-
diac defects and a normal karyotype, Moore et al [14]
found that 17 (3.15%) had a 22q11.2 microdeletion
diagnosed by FISH. In a study of 27 fetuses with in-
trauterine growth restriction, congenital heart defects
and a normal G-banded karyotype, Chen et al [15]
found that three (11.1%) had a 22q11.2 microdeletion
and two (7.4%) had a subtelomeric deletion, including
monosomy 21q22.3 and monosomy 1p36.3. In a review
of 52 patients with DGS, Minier et al [16] found that
only six (11.5%) were diagnosed during the prenatal
period, 12 (23.1%) were diagnosed by pathologic exam-
ination and 34 (65.4%) were diagnosed during infancy.
There is marked phenotypic variability among patients
with a 22q11.2 deletion [17]. In a study of 30 individ-
uals (19 adults and 11 children) with a 22q11.2 deletion
following the diagnosis in their relatives, McDonald-
McGinn et al [17] found that 60% (18/30) had no vis-
ceral anomalies, and only 32% (6/19) of the adults
and 55% (6/11) of the children with a 22q11.2 dele-
tion had major findings.
The 22q11 region is susceptible to chromosomal
rearrangements leading to DGS/VCFS, cat-eye syn-
drome and t(11;22)der(22) syndrome, of which all
three breakpoint regions harbor similar low-copy repeat
sequences, also known as LCR22s [18,19]. Homolo-
gous recombination events between LCR22s during
meiosis have been implicated in DGS/VCFS and cat-
eye syndrome, and the sites of chromosome breakage
on 11q23 and 22q11 in der(22) syndrome occur in the
unstable AT-rich palindromic sequences leading to non-
homologous recombination mechanisms [19–22].
About 90% of the patients with a 22q11.2 microdele-
tion have a common approximately 3-Mb deletion,
and 7% of the patients have a smaller, nested, approxi-
mately 1.5-Mb recurrent deletion, all located in the
22q11.2 proximal deletion region [23,24]. Recently,
Ben-Shachar et al [24] identified atypical deletions
located in the 22q11.2 distal region. Patients with an
atypical deletion have a 22q11.2 microdeletion distal
to the common deletion region and manifest a pheno-
type distinct from DGS/VCFS [24].
DGS (OMIM 188400), a developmental field defect
of the third and fourth pharyngeal pouches, is charac-
terized by hypocalcemia arising from parathyroid hypo-
plasia, thymic hypoplasia, and outflow tract defects of
the heart including tetralogy of Fallot, truncus arterio-
sus, and interrupted aortic arch. Most cases with DGS
result from a deletion of chromosome 22q11.2. How-
ever, about 10–15% of patients do not have the stan-
dard 22q11.2 deletion but have other genetic causes,
such as distal deletions of chromosome 10p and chro-
mosome 4q, unbalanced chromosomal translocations,
atypical deletions of 22q11.2, and UFD1L haploin-
sufficiency [25–32]. Although FISH, ultrarapid FISH
and multiplex ligation-dependent probe amplification
are highly accurate tests for detecting the standard
22q11.2 microdeletion [33–35], routine aCGH has the
advantage of detecting uncharacterized chromosomal
imbalances and atypical 22q11.2 microdeletions, as
well as refining the 22q11.2 deletion breakpoints
[36,37] in the event of in utero detection of a fetus with
congenital heart defects.
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